Buy Max Healthcare Ins: IIFL Securities's Target Price Rs 1230
IIFL Securities recommends buying Max Healthcare Insurance shares, with a target price of Rs 1230, based on an analysis of the company's strong fundamentals. The current market price stands at Rs 1196.95, indicating a potential upside of approximately 2.7%. This buy call is supported by the brokerage firm's positive outlook on the healthcare sector and Max Healthcare's position as a leading provider of healthcare services in India.
About Max Healthcare Ins:
Max Healthcare Institute Limited, listed on the National Stock Exchange (NSE) as "Max Healthcare Ins," is a leading Indian healthcare provider. It operates a network of hospitals, diagnostic centers, and day care facilities across India, offering a comprehensive range of healthcare services including primary care, specialized medical treatment, preventive care, and emergency services. The company also provides health insurance products and services through its subsidiary, Max Bupa Health Insurance. Max Healthcare Institute is a part of the Max Group, a diversified conglomerate with interests in healthcare, life insurance, general insurance, and real estate.
52 Week Price Trend:
Max Healthcare Institute Limited (Max Healthcare), a leading healthcare provider in India, has witnessed a significant appreciation in its stock price since reaching its 52-week low of Rs. 630.75. As of today, the company's shares are trading at Rs. 1196.95, marking a substantial increase of 89.6% over the past year. This surge in stock price reflects the company's strong financial performance, expansion plans, and positive outlook for the healthcare sector in India. Max Healthcare's current market capitalization stands at approximately Rs. 26,000 crores.
Stratzy's MOST Analysis:
MAXHEALTH has been assigned a BB rating by Stratzy's MOST framework, indicating moderate fundamental risks. This assessment considers the company's management effectiveness, future prospects, financial stability, and market trend. The rating reflects the company's solid management, positive outlook, and sound financial position. However, it also highlights areas where improvements could be made, such as enhancing operational efficiency and addressing potential market headwinds. Overall, the BB rating suggests that MAXHEALTH is a financially sound company with good growth potential, but investors should be aware of potential risks before making investment decisions.
Company's Fundamentals:
Max Healthcare Ins(NSE:MAXHEALTH) is currently trading at a Stock PE of 103.94, indicating that investors are willing to pay ₹103.94 for every ₹1 of earnings. Its PB Ratio stands at 12.51, implying that investors are paying ₹12.51 for every ₹1 of book value. The Dividend Yield of 0.13% suggests that investors can expect to receive ₹0.13 in dividends for every ₹100 invested in the stock. These metrics provide insights into the company's valuation, profitability, and dividend-paying capacity, helping investors make informed decisions.
Fundamental and Technical information provided in this blog were last updated on 17 Dec, 2024
Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.